UseCases_ArguminSci_Discourse  

PubMed:24691501 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-115 DRI_Background denotes Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
T2 116-253 DRI_Background denotes Ductal carcinoma in situ (DCIS) is a nonmalignant lesion of the breast with the potential to progress to invasive ductal carcinoma (IDC).
T3 254-421 DRI_Background denotes The disappearance and breakdown of the myoepithelial cell layer and basement membrane in DCIS have been identified as major events in the development of breast cancer.
T4 422-549 DRI_Approach denotes The MCF10DCIS.com cell line is a well-established model, which recapitulates the progression of breast cancer from DCIS to IDC.
T5 550-776 DRI_Approach denotes We have previously reported that a novel Gemini vitamin D analog, 1α,25-dihydroxy-20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol (BXL0124) is a potent inhibitor of the growth of
T6 777-802 Token_Label.OUTSIDE denotes MCF10DCIS.com xenografted
T7 803-841 DRI_Approach denotes tumors without hypercalcemic toxicity.
T8 842-981 DRI_Approach denotes In this study, we utilized the MCF10DCIS.com in vivo model to assess the effects of BXL0124 on breast cancer progression from weeks 1 to 4.
T9 982-1186 DRI_Approach denotes Upon DCIS progression to IDC from weeks 3 to 4, tumors lost the myoepithelial cell layer and basement membrane as shown by immunofluorescence staining with smooth muscle actin and laminin 5, respectively.
T10 1187-1374 DRI_Background denotes Administration of BXL0124 maintained the critical myoepithelial cell layer as well as basement membrane, and animals treated with BXL0124 showed a 43% reduction in tumor volume by week 4.
T11 1375-1473 DRI_Background denotes BXL0124 treatment decreased cell proliferation and maintained vitamin D receptor levels in tumors.
T12 1474-1636 DRI_Approach denotes In addition, the BXL0124 treatment reduced the mRNA levels of matrix metalloproteinases starting at week 3, contributing to the inhibition of invasive transition.
T13 1637-1816 DRI_Outcome denotes Our results suggest that the maintenance of DCIS plays a significant role in the cancer preventive action of the Gemini vitamin D BXL0124 during the progression of breast lesions.